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Abstract Only a small fraction of drugs widely used in
neonatal intensive care units (NICU) are specifically au-
thorized for this population. Even if unlicensed or off-label
use is necessary, it is associated with increased adverse
drug reactions, which must be carefully weighed against
expected benefits. In particular, renal damage is frequent
among preterm babies, and is considered a predisposing
factor for the development of chronic kidney disease in
adulthood. Apart from specific conditions affecting pre-
mature neonates (e.g. respiratory distress syndrome, peri-
natal asphyxia), drugs play an important role in impairing
renal function because of well-known nephrotoxicity and/
or interaction with renal developmental factors. From a
review of the available studies on drug use in NICU pa-
tients, we identified and described the most commonly
administered drugs that are correlated to renal damage.
Early detection of kidney injury is becoming an essential
aspects for clinicians because of the limited number of
biomarkers applicable in the neonatal population. Postnatal
changes of biochemical processes that influence pharma-
cokinetic and pharmacodynamic aspects need to be further
investigated in order to better understand the mechanisms
of drug toxicity in this population. The most promising
strategies for dose adjustment and therapeutic schemes are
discussed. The purpose of this review was to describe
current knowledge on drug use among premature babies
and their implication in kidney injury development, as well
as to highlight available strategies for early detection of
renal damage.
Key Points
Drug-related injuries in preterm neonates involving,
in particular, the kidney and acute renal damage
often turn out to have long-term sequelae in
adulthood (e.g. hypertension).
Several molecules have been identified as potential
biomarkers for the early detection of renal damage in
neonates, however they still need to be validated.
Regulatory agencies have identified the need for age-
appropriate pharmaceutical research in pediatrics,
indicating specific initiatives for the neonatal
population.
1 Introduction
Preterm neonates are defined as newborns less than
37 weeks of gestational age, including very low birth-
weight infants (weight \1500 g) and extremely low birth-
weight infants (weight \1000 g). The number of babies
born preterm is rising every year [1] and, thanks to im-
proved perinatal care, their survival rate has increased over
time (almost 90 % of neonates born weighing 501–1500 g
survived after discharge from the neonatal intensive care
unit (NICU) [2]), thus creating a novel population that have
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now reached early childhood. The percentage of unautho-
rized and off-label use of drugs in the NICU is very high
(up to 90 %) [3] and clinicians often have to manage
clinically needed treatments without clear evidence on their
efficacy and/or safety, and only with a partial understand-
ing of precise dose adjustment and pharmacokinetics. The
long-term effects of these treatments are even more
uncertain.
This situation reflects difficulties in performing research
in term and preterm neonates; the feasibility of clinical
trials is compromised by ethical (high vulnerability) and
technical issues (multi-organ immaturity, lack of self-
assessment, need for specific formulation, etc.), the number
of neonates with a given disorder in each individual center
is limited, and there is high variability in practices (drugs
and duration of treatment, monitoring, medical care).
Due to its central role in drug excretion, the kidney is a
major target for toxicity with a contribution from drugs,
and also many typical conditions affecting premature ba-
bies (e.g. respiratory distress syndrome, perinatal asphyxia,
severe infections, sepsis, hemodynamic instability) (Fig. 1)
[4].
The aims of this review were (1) to describe current
knowledge on drug use among NICUs; (2) the implication
of the most commonly used therapeutic treatments in kid-
ney injury development; and (3) to highlight available
strategies to monitor renal safety profiles of pharmaco-
logical treatments among preterm neonates. To this end, we
carried out a search in Pubmed/MEDLINE (time restric-
tions: 2006–October 2014) to select key publications in the
English language, using a combination of the following
keywords (free text search strategy): ‘preterms’, ‘preterm
neonates’, ‘NICU’, ‘drug utilization’, ‘drug use’, ‘AKI’,
‘drug-induced kidney injury’, and ‘drug-induced renal
damage biomarkers’. In order to identify possible addi-
tional references, the most authoritative publications were
identified and a snowballing search was performed in some
key reviews.
2 State of the Art on Drug Development and Use
in Preterm Neonates
2.1 Regulatory Aspects
The general lack of appropriate pharmaceutical formula-
tions for children promoted legal obligation to perform
studies to support use in the pediatric population [5]. In
particular, from 1997 the US FDA with the ‘Modernization
Act’ and from 2002 the European Medicines Agency
(EMA) with the consultation paper ‘Better Medicines for
Children’ undertook actions to promote clinical trials in
children for both authorized and investigational medicinal
products [6, 7]. These documents were then implemented
in the ‘Pediatric Research Equity Act’ (FDA, 2003) [8] and
the ‘Regulation on Medicinal Products for Paediatric Use’
(EMA, 2006) [9].
The main objectives of the regulatory actions were to
ensure high-quality research into the development of
medicines for children, to make sure that the majority of
them are specifically authorized for such use, and to ensure
the availability of high-quality information [10]. To
Fig. 1 Interplay between kidney, exposures, risk factors and outcomes
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support companies in new development strategies, a recent
FDA regulatory initiative (FDA Safety and Innovation Act
[11]) included the neonatal population among its main
topics; specific expertise in neonatology is requested within
the Office of Pediatric Therapeutics and the Pediatric Re-
view Committee. In Europe, the EU Regulation of 2006
established the Paediatric Committee (PDCO), within the
EMA, which was responsible for the evaluation of Pedi-
atric Investigation Plans (PIPs) presented by companies as
mandatory programs for the pediatric indication [9]. Other
health organizations have also faced the problem of ap-
propriate drug use in the pediatric population; the World
Health Organization (WHO) developed a program on
medicines for children, resulting in the WHO Model For-
mulary on how to use essential medicines for children [12].
Several National Health Institutes published guidebooks on
the use of widely administered drugs in children (e.g.
Italian Institute of Health [13]).
Some results of the legislative actions undertaken so far
have been provided by the approval of the 500th pediatric
label change in 2013 by the FDA [14], the 221 changes
regarding safety and efficacy, for submission of old or new
studies, and 89 additions of dosing information for children
in the EU [15]. Despite this, neonates (especially preterm
newborns) are neglected in clinical trials and a worldwide
gap of knowledge on the use of medicinal products in
neonates still persists [16–27].
2.2 Unlicensed and Off-Label Drug Use Among
Preterm Neonates
Definitions for ‘unauthorized’ (or ‘unlicensed’) and ‘off-
label’ use of drugs may differ among authors but, in gen-
eral, a medicinal product is considered unauthorized if it
has no indication for the specific population, and is off-
label when not included in the approved labeling; for ex-
ample, a change in the formulation (i.e. to obtain a lower
dose) or in the method of administration [16, 17, 23, 25, 26,
28].
Trials recruiting neonates have grown over time and
have increased sixfold in the past decade, but registered
trials targeting neonates still represent a minority. Ana-
lysing the ClinicalTrials.gov database, among all trials
registered 22 % (30,912) involved the pediatric population
and only 0.2 % (288) targeted neonates [24]. Among
studies involving preterm neonates from the same inter-
national database (www.clinicaltrials.gov), 238 open
studies emerged, mostly carried out in the US (89) and
Europe (79) (Table 1). In Europe, France and the UK had
the highest number of open studies in this population (26
and 12, respectively), followed by Germany (8), Italy (7),
and Spain (7). Open studies represent 39.3 % of the total
(606) worldwide studies in this population. Trials on
preterm newborns involving medicinal products focused, in
particular, on anti-infective agents (51), analgesics (24),
pulmonary surfactants (9), and drugs for the management
of patent ductus arteriosus (PDA), i.e. indomethacin (6),
acetaminophen (paracetamol; 6) and ibuprofen (3).
Recent studies investigated the off-label and unlicensed
use of drugs in the European pediatric population
(Table 2); however, these studies showed great hetero-
geneity in their methods (design, duration, definition of off-
label use, etc).
Haslund-Krog et al. [25] took into account the 100 most
used drugs in children from the national Danish database and
found that 13 are used off-label (defined as one of the fol-
lowing: absence of pediatric information, lack of clinical
data, contraindication for use in children, drug substances
being an extemporaneous preparation or unlicensed).
Twenty-one percent of drug substances reviewed had a PIP,
and only six (28.6 %) of these included preterms and new-
borns in their PIPs. A study in Finland, carried out to verify
the impact of the European Pediatric Regulation, actually
found that off-label use in newborns was higher in 2011 than
in 2001 (51 vs. 22 %), whereas prescriptions of unauthorized
medicines decreased from 31 % in 2001 to 25 % in 2011
[26]. The prevalence of off-label use in NICUs was reported
to be 46.5 % in Italy [16] and 39 % in Ireland [17].
In the US, less than 0.5 % of all drug exposures in
neonates was approved by federal legislation. Revision of
the FDA database for studies submitted between 1997 and
2010 involving the pediatric population, showed 406 pe-
diatric labeling changes, of which only 6 % included new
neonatal information [20].
Several reasons explain why only few clinical trials are
performed in neonates, i.e. ethics problems, parent distrust,
low economic interest by drug companies, and low funds
for specific age-related studies [29]. Moreover, feasibility
problems occur in studying drugs in newborns according to
Table 1 Number of trials recruiting neonates. Search strategy per-
formed without time restrictions, using the keyword ‘preterm neo-
nates’ (last access, 16 October 2014)
Closeda Openb
Total 368 238
North America 161 112
Europe 85 79
Asia 43 15
Middle East 27 20
Africa 21 10
South America 16 5
Pacific 2 3
Central America 0 2
a Excluding ‘unknown status’
b International studies are counted only once in the Total section
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good clinical practice, i.e. the amount of blood required for
measuring safety laboratory values when added to the
volume required for pharmacokinetic measurements
quickly exceeds safe limits; additionally, organ function is
difficult to measure, and even harder is the evaluation of
efficacy without gold standards [18]. Other strong obstacles
to research are the limited number of neonates with a given
disease in each individual center, highly variable practices
(drugs and duration of treatment, prophylaxis vs. treatment,
monitoring, medical care, including type of ventilation)
and lack of support for networks.
Although off-label or unlicensed use of medicines does
not necessarily imply inappropriate use (i.e. benefits out-
weigh potential risks) and is often necessary, it has been
associated with increased adverse drug reactions (ADRs) in
children [30] and neonates [19]. Risks factors in newborns
are the immaturity of most organ functions and the de-
velopmental changes occurring in the postnatal period,
which could significantly influence plasma concentration
of medicines, their safety, and their efficacy [31]. Since
neonates frequently suffer from multiple concomitant
conditions, a combination of medicinal products may result
in a higher risk of interactions [19].
3 Kidney Development Steps and Pharmacological
Implications
Term neonates (i.e. between 37 and 41 weeks of gestation)
possess a full set of nephrons, whereas growth retardation,
prematurity, or nephrotoxic drugs administered to the
mother negatively affect the total number of nephrons in
Table 2 Studies on drug use among NICU patients
References Country Aims and type of study Type and number
of pediatric wards
Study period No. of neonates
(preterms)
Laforgia
et al. [16]
Italy Evaluate the unlicensed and off-label use
of drugs in the NICU
Prospective study
8 NICUs 1 May
2011–31
May 2011
126
(77; \37 weeks
GA)
Haslund-
Krog
et al. [25]
Denmark Determine the off-label use of drugs in the
pediatric population and whether these
drugs have a PIP
Retrospective study (analysis of drug
substance’s defined daily dose, extracted
from national Danish database).
General and university
department, outpatient clinics,
child and youth psychiatric
departments
1 November
2011–30
October
2012
–
Lindell-
Osuagwu
et al. [26]
Finland Evaluate the differences in off-label use
and unauthorized medicines in the
pediatric wards in 2001 compared with
2011
Prospective study
1 NICU, 1 general pediatric ward
and 1 pediatric surgical ward
2 weeks in
April and
May 2011
25 (14; \37 weeks
GA)
Kieran
et al. [17]
Ireland Determine the extent of unlicensed and off-
label prescribing in an NICU
Prospective study
1 NICU 1 February
2012–31
March
2012
110
(30; \32 weeks
GA)
Dessı` et al.
[27]
Italy Determine the off-label use of drugs in the
NICU and neonatal pathology unit
Prospective study
1 NICU 1 month in
March
2007
38
(16; \ 37 weeks
GA)
Neubert
et al. [28]
Germany Describe drug use in an NICU, and
investigate the licensing status of the
drugs
Prospective study
1 NICU December
2004–
October
2005
183
(100; \37 weeks
GA)
Dell’Aera
et al. [22]
Italy Evaluate the unlicensed and off-label use
of drugs in the NICU
Prospective study
1 NICU 1 July–31
August
2004
34 (19; \37 weeks
GA)
Clark et al.
[75]
North
America
Identify the most commonly reported drugs
for NICU patients
Retrospective study
220 NICUs January
1996–
April 2005
253,651
Average GA:
35 weeks
Range:
33–38 weeks
NICU neonatal intensive care unit, GA gestational age, PIP Pediatric Investigation Plan
A. Girardi et al.
the neonate [32]. Among drugs shown to limit the forma-
tion of nephrons, high steroid level exposure of pregnant
women (i.e. dexamethasone administration to advance
maturation of the fetal lung in premature delivery) seems to
impair fetal nephrogenesis and lead to reduced nephron
number in the newborn [33]. Since the renin-angiotensin
system is essential for tubular development during fetal
life, angiotensin-converting enzyme inhibitors and an-
giotensin receptor antagonists during pregnancy may re-
duce nephron formation [34] and cause renal tubular
dysgenesis [35]. Additionally, maternal use of NSAIDs as
tocolytic agents affects renal development, leading to
tubular alterations and low nephron numbers [36, 37].
Although evidence of ongoing nephrogenesis has been
recorded up to 40 days after birth in neonates less than
30 weeks of gestational age [38, 39], those born at 23 or
24 weeks do not continue nephrogenesis until 36 weeks, as
in normal gestations. Furthermore the ex utero environment
makes kidney maturation particularly vulnerable (e.g. acute
kidney injury (AKI) in early neonatal life, perinatal growth
restriction, nephrotoxic drugs) [40]. The kidneys of pre-
mature babies show a higher number of histologically ab-
normal glomeruli and an increased glomerular volume
compared with term neonates [39].
After birth, a sudden change in environmental condi-
tions triggers the start of renal function and clearance, with
marked difference in postnatal development between very
low birth-weight (VLBW), premature, and term neonates,
mainly because of immaturity and prolonged adaptation of
extrauterine life. Normal glomerular filtration rate (GFR)
maturational changes after birth are driven by the rise in
renal blood flow (RBF), and alterations in intrarenal blood
perfusion patterns. Growth and maturation of renal tubules
and tubular processes will result in a more sophisticated
regulation of acid base and electrolyte balance. RBF in
premature babies is reported to be less than half the RBF
value in term neonates, and although it progressively in-
creases over time, it takes longer for preterms to reach the
adult rate compared with term neonates [41]. Both
glomerular and tubular renal functions are affected by
gestational age at birth as well as postnatal age. Recent data
suggest that, compared with maturational patterns in term
neonates, the maturational creatinine clearance in preterm
neonates matures slower, while there is already a higher
capacity for postnatal tubular maturation in preterm neo-
nates and at the age of 1 month [42]. Maturation of these
renal tubular processes will also affect the capacity to
dispose excess sodium or water via the kidney soon after
birth. This reflects the need to redistribute body fluids and
the ability to maintain a negative water and sodium bal-
ance. Since high sodium excretion is inversely proportional
to maturity, this process results in greater and more pro-
longed losses in premature newborns, requiring sodium
administration for the first several weeks of life [43]. Im-
maturity of renal functions also leads to the imbalance of
other electrolytes, such as potassium, calcium, and phos-
phorus, resulting in hyperkalemia and hypocalcemia, and
this last condition correlates with a high risk of tetany or
decreased cardiac contractility [44]. The kidney plays an
important role in the maintenance of the acid-base balance,
in cooperation with the respiratory system; since preterm
babies possess an immature regulatory mechanism, they
tend to display intracellular acidosis due to imbalanced
acid-base homeostasis [45]. Moreover, the lower response
of the adrenal gland to aldosterone, which is involved in
fluid and electrolyte balance regulation through the im-
provement of renal sodium absorption, may also contribute
to the negative sodium and water balance seen in premature
newborns [44].
4 Role of Drugs in Renal Damage
4.1 Drug-Induced Kidney Injury
Since the kidney is the main organ for excretion of a drug
and its metabolites, preterm neonates are at higher risk of
overdosing due to immature renal function [32]. The renal
contribution to excretion occurs at several levels, i.e.
glomerular filtration, tubular secretion and reabsorption, or
intracellular enzymatic processing, mainly in proximal
tubular cells [46, 47]. Preterm babies show specific glom-
erotubular imbalance because GFR sharply increases after
birth while tubular secretion matures slower, but more
steadily, to result in a proportional higher capacity for
postnatal maturation of renal tubular function [42]. Phar-
macokinetic and pharmacodynamic parameters differ not
only between preterm and term neonates but also among
preterms. As a matter of fact, the cut-off for achieving
nephrogenesis, and thus the capacity of drug renal
elimination, is assumed at the 33rd week of gestational age
[32].
4.1.1 Acute Kidney Injury
AKI classification has recently been reviewed by the in-
ternational workgroup on kidney diseases (Kidney Dis-
eases: Improving Global Outcomes; KDIGO), retaining the
Acute Kidney Injury Network (AKIN) and Risk, Injury,
Failure, Loss and End-stage kidney disease (RIFLE) stag-
ing criteria. The KDIGO criteria defined the abrupt de-
crease in kidney function according to changes in serum
creatinine and urine output, whereas for children younger
than 18 years of age, the evaluation of GFR is additionally
required (stage 3 criteria included an acute decrease in
estimated GFR to less than 35 mL/min/1.73 m2) [48].
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AKI is common in the NICUs; the incidence is 15 % in
near-term/term newborns admitted to the NICU [49], 19 %
in premature neonates, and 18 % in very low birth neonates
[50]. Askenazi et al. [49] found that low birth weight, lower
gestational age, male sex, and lower 5-min Apgar score in
near-term/term neonates were associated with AKI.
Moreover, AKI correlates with higher mortality rates in
both term and preterm babies, and in VLBW neonates it is
considered an independent predictor of mortality [50].
Many of the specific conditions affecting preterm neonates
could reduce GFR, or even cause AKI; for instance, res-
piratory distress syndrome is associated with a significant
AKI frequency [51], as well as perinatal asphyxia [52].
Furthermore, severe infections and sepsis are considered
risk factors of AKI [53, 54]. In addition, many of the
widely used therapies and combinations in NICU hospi-
talized patients could cause kidney injury, either because of
their well-known nephrotoxicity (i.e. aminoglycosides) or
their impact on immature renal functions.
4.1.2 Chronic Damage
Immature kidneys of preterm neonates after early exposure
to pharmacological treatments may undergo further im-
pairment. Soon after birth, glomerular volume is abnormally
increased in premature newborns, and a greater percentage of
their glomeruli are histologically anomalous, with dilatation
of the Bowman’s space [39]. Many nephrologists proposed
that individual nephron enlargement (i.e. an increased total
surface area available for renal work, potentially reflecting
glomerular hyperfiltration) was a compensatory mechanism
to maintain normal GFR [55]. However, this adaptive re-
sponse leads to sodium retention and systemic hypertension,
while glomerular hyperfiltration disrupts renal autoregula-
tory mechanisms, generating intraglomerular hypertension
and proteinuria [56–59]. As a consequence, nephron number
can further decrease [56, 60]. Since nephrons cannot be re-
generated [61], renal injury can turn into chronic damage. As
proof of this, renal diseases can worsen in the long-term,
especially in immature babies [62]; low birth weight was
strictly correlated with increased long-term risk of chronic
kidney disease (CKD) in adolescence [63] and adulthood
[64]. The same was noticed in neonates with kidney injury in
the postnatal period who rarely experienced complete renal
regeneration and damage due to AKI turning out to be irre-
versible [40]. A recent study among pediatric patients with a
diagnosis of AKI found that 10.3 % developed CKD within
1–3 years after diagnosis, and nearly 50 % of the cohort was
affected by hypertension, reduced GFR, or hyperfiltration
[65], which are correlated with a risk of CKD. Similarly,
other trials showed that children with AKI with different
etiology all have an increased risk of developing CKD in the
pediatric years [66, 67].
4.1.3 Classification of Drug-Induced Kidney Injury
The clinical classification of renal damage is challenging be-
cause symptoms are non-specific and simply consist of urine
Fig. 2 Classification of drug-induced kidney injuries [68–74]. NSAIDs non-steroidal anti-inflammatory drugs, ACEIs angiotensin II-converting
enzymes, ARBs angiotensin II-receptor blockers
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flow interruption. The pathophysiological classification of
kidney injuries is based on the mechanism of renal dysfunc-
tion: (a) hemodynamically mediated, (b) glomerulonephritis,
(c) acute tubular necrosis, (d) interstitial nephritis, (e) papil-
lary necrosis, and (f) obstructive nephropathy (Fig. 2).
(a) Hemodynamically-mediated renal failure arises when
mechanisms of maintenance of intra-glomerular pres-
sure are impaired, e.g. decrease in blood flow to the
kidney, vasoconstriction of glomerular afferent arte-
riolar, or vasodilatation of glomerular efferent arteri-
oles. The autoregulation of intraglomerular pressure is
essential to maintain GFR and urine output, and the
main influencing factors are circulating prostaglan-
dins (vasodilatation of afferent arterioles) and circu-
lating angiotensin II (vasoconstriction of efferent
arteriole). Thus, non-steroidal anti-inflammatory
drugs (NSAIDs), angiotensin II-converting enzymes
(ACEIs), angiotensin II-receptor blockers (ARBs),
and calcineurin inhibitors are among the drugs
inducing this type of injury [68].
(b) Renal damage in glomerulonephritis syndrome is due
to inflammation reactions, protein infiltration, and
cell-mediated immunity processes. Decreased serum
albumin levels induce over-production of proteins by
the liver, which contributes to the development of
nephrotic syndrome, i.e. proteinuria, hypoalbumine-
mia, hyperlipidemia, and edema. Treatment with
NSAIDs, ampicillin, rifampin, foscarnet, and lithium
causes renal failure through this mechanism [68, 69].
(c) Acute tubular necrosis is characterized by tubular cell
death as a result of ischemic effects of toxic exposure
to agents such as aminoglycosides and amphotericin
B. Tubular cells have the highest exposure to
circulating toxins because they concentrate and reab-
sorb the glomerular filtrate; tubular damage is medi-
ated by the alteration of mitochondrial function,
interfering with tubular transport, increasing oxidative
stress, or forming free radicals [70, 71].
(d) Administration of b-lactam antibiotics, vancomycin,
NSAIDs, and calcineurin inhibitors correlates with acute
allergic interstitial nephritis, which is mediated by
inflammatory reactions in the renal tubules and intersti-
tium [68, 70]. Most of those cases occur as a hypersen-
sitivity reaction to a substance, thus heterogeneous classes
of drugs may be the cause of this type of renal injury.
(e) Papillary necrosis is associated with the use of
analgesic agents, such as acetaminophen and
NSAIDs, but also kidney infections are reported to
cause this damage [72, 73].
(f) Another type of injury is the mechanical obstruction
of renal function; some drugs (acyclovir, ciprofloxac-
in, sulfonamides, methotrexate) or metabolites could
precipitate, after glomerular filtration, into tubules and
act as mechanical obstruction of urine flow, leading to
renal insufficiency [70, 74].
4.2 Treatment-Related Renal Damage by Drug
Class
Few and heterogeneous data are available on drug use in
NICUs. In most cases, only unauthorized and off-label drug
use was investigated, in order to understand the impact of
the European Pediatric Regulation [16, 17, 22, 25–27],
whereas Neubert et al. [28] and Clark et al. [75] reported
overall medication use in German and US NICUs, re-
spectively (Table 2). In these national reports, antimicro-
bial and cardiovascular agents, analgesics and respiratory
drugs are the most commonly used in preterm neonates [16,
17, 25, 26, 28, 75]; antibiotics have the highest exposure
rates and also the highest differences between nations in
terms of drug substances. In the US, ampicillin and gen-
tamicin have been reported as the most frequently used
antibiotics, followed by cefotaxime and vancomycin [75];
the most used are piperacillin and vancomycin in Germany
[28], cefotaxime in Finland [26], ampicillin and amikacin
in Italy [16], and gentamicin in Ireland [17]. This hetero-
geneity in the choice of antibiotics is related to the lack of
guidelines and comparative clinical studies, as documented
by a Cochrane review comparing different antibiotic regi-
mens for suspected late-onset sepsis in newborns [76].
Aminoglycosides, such as amikacin and gentamicin, are
widely prescribed in NICUs for the prevention and treat-
ment of infections. Aminoglycosides have well-known
nephrotoxic effects; they are partially reabsorbed into
proximal tubular cells and their cationic charge facilitates
their binding to membrane phospholipids of tubular ep-
ithelial cells. This leads to the activation of intracellular
transport into lysosomes, where they bind to phospholipids
and inhibit phospholipase activity. This process pre-
cipitates in acute tubular necrosis development, as the re-
sult of accumulation of phospholipids, interruption of
cellular functions, and cell death [77]. Aminoglycoside-
induced AKI is characterized by elevation of serum crea-
tinine, blood urea nitrogen, and reduction of urine output,
but is reversible with drug discontinuation. Age, coad-
ministration of other nephrotoxic drugs, and duration of
therapy are among the factors increasing the risk of
aminoglycoside-induced nephrotoxicity [68]. It has also
been investigated whether different regimens of amino-
glycoside treatment (gentamicin ‘once a day’ vs. ‘multiple
doses a day’) may reduce nephrotoxicity, but no changes
were found [78]. Recent studies on aminoglycoside use in
preterm neonates evidenced that GFR levels were, sur-
prisingly, almost unchanged, at least after short-term
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administration in the early postnatal period at therapeutic
dosages [79].
Another class of antibacterial agents used for both the
prevention and treatment of recurring infections in the
NICU are b-lactam antibiotics, particularly ampicillin,
piperacillin, and cefotaxime. The administration of these
molecules has been correlated with nephrotoxicity, par-
ticularly with acute interstitial nephritis, affecting the renal
tubules and interstitium with consequent acute renal failure.
b-Lactam-induced nephrotoxicity is mediated by hyper-
sensitivity reactions, believed to be cell mediated as T cells
are the main pathological interstitial finding; it is also
possible to find lymphocytes, monocytes, and eosinophils in
the interstitial infiltrate. Renal effects come along with
typical systemic manifestations, such as fever, eosinophilia,
and skin rash, which are not commonly seen in acute in-
terstitial nephritis caused by other drug classes. Kidney
injury is reversible after discontinuation of the drug, and it
may take weeks to months to be complete. In this case,
glucocorticoid therapy may improve recovery [70, 80].
Acute interstitial nephritis can also result from vancomycin
treatment, as a consequence of antigen precipitation into the
interstitium, which triggers an immune reaction [70, 81].
Amphotericin B is the most nephrotoxic antimicrobial
drug and remains the drug of choice to treat severe systemic
fungal infections (also in neonatal wards). Tubular cell
toxicity due to amphotericin B depends on its binding to
sterols of cell membranes and consequent alteration of
membrane permeability to sodium; the increase of intra-
cellular sodium concentration and the activation of vaso-
constrictor prostaglandins lead to vasoconstriction of renal
vessels. As a consequence, RBF and GFR decrease and is-
chemic injury occurs [82]. Amphotericin B-induced distal
tubulopathy is evidenced by increased serum urea and
creatinine concentrations, as a result of decreased GFR, and
hypokalemia, metabolic acidosis, hypomagnesemia, and
loss of urine concentration ability [83]. Risk factors for
amphotericin B nephrotoxicity include renal insufficiency,
volume depletion, large individual and cumulative doses,
and coadministration of other nephrotoxic drugs [84, 85].
Because of the clinical usefulness of amphotericin B,
strategies were sought to decrease its adverse effects, e.g. its
lipid-associated formulation, which showed similar efficacy
but lower nephrotoxicity. However, the cost of these new
formulations limited their use to patients at highest risk of
renal failure [86]. To prevent amphotericin B nephrotoxicity
in children, Goldman and Koren [83] suggested introducing,
as standard care, sodium supplementation pre- and post-in-
fusion to reduce vasoconstriction, as well as close
monitoring of renal function over a lipid-associated formu-
lation, unless significant nephrotoxicity develops [86].
Among diuretics, furosemide is the preferred drug in the
NICUs [16, 28, 75] and, along with the other ‘loop’
diuretics, it increases the rate of urine flow and sodium
excretion by affecting the delivery of solutes out of the loop
of Henle. Furosemide intake is associated with water and
electrolyte imbalances, particularly hyponatremia, hy-
pokalemia, and hypochloremic alkalosis. Moreover, hy-
percalciuria occurs with long-term furosemide therapy, and
the risk of developing nephrocalcinosis is higher in low
birth-weight neonates (underdevelopment of renal func-
tions, such as decreased GRF, low citrate excretion and
alkaline urine). It is also reported that, in most cases, the
discontinuation of treatment is associated with resolution of
the renal calcification. The use of furosemide in neonates
may also cause ototoxicity, and strategies have been studied
in order to avoid hearing loss, including slow continuous
infusion and short-term administration, and it is strongly
recommended to avoid the association of furosemide with
aminoglycosides. Additionally, furosemide enhances
prostaglandin E2 synthesis, which acts as a potent dilator of
the PDA, thus inhibiting the effect of drugs used to close it.
Careful monitoring is needed in babies with respiratory
distress syndrome treated with furosemide because they are
at higher risk of precipitation of a symptomatic PDA [87].
In neonates, short-term treatment with NSAIDs (espe-
cially ibuprofen and indomethacin) is mostly for the man-
agement of PDA. Although the overall risk-benefit profile
of this drug class is positive, NSAIDs are implicated in AKI
development in patients with pre-existing renal diseases,
poor RBF, or when other nephrotoxic agents are coadmin-
istered (i.e. aminoglycosides, diuretics). In these cases,
activation of the renin-angiotensin system and the rise of
circulating catecholamines stimulate renal prostaglandin
production, which protects renal perfusion and glomerular
filtration. The inhibition of prostaglandin synthesis by
NSAIDs may lead to a rapid decline of renal function after
only a few doses. In addition, NSAIDs are also responsible
for acute interstitial nephritis and glomerulonephritis [77].
Renal failure is reversible after discontinuation.
A new therapeutic approach to close PDA in preterm
neonates consists of the use of acetaminophen instead of
classic NSAID treatment. Acetaminophen is widely pre-
scribed among neonates to treat moderate pain or fever, and it
seems to have a better safety profile than ibuprofen and in-
domethacin; however, the different therapeutic scheme used
for the management of PDA has not been investigated in
terms of respiratory and renal long-term outcomes [88].
When a drug with nephrotoxic potential is administered,
drug-induced renal damage is reported to be reversible
after prompt discontinuation of the offending agent, but it
is also reported that coadministration of other nephrotoxic
medications are always to be avoided (Table 3). However,
preterm babies are characterized by ongoing nephrogenesis
in the first postnatal period, which could be irreversibly
impaired by drug exposure, and cellular injury to glomeruli
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or tubules may impair long-term renal functional capacity
and increase susceptibility to renal disease later in life [40].
Moreover, the management of NICU patients entails the
treatment of several concomitant diseases (such as respi-
ratory distress syndrome, PDA, and infections), thus re-
quiring the administration of a combination of potentially
nephrotoxic medicinal products. There are well-known
complications as a result of the association of two or more
of the widely used drugs in NICUs. Attention should be
paid to the concomitant use of furosemide and in-
domethacin or ibuprofen because of the increased risk of
symptomatic PDA in neonates with respiratory distress
syndrome; when used in combination with aminoglyco-
sides, furosemide may also compromise hearing functions.
It has been reported that NSAID treatment alters the renal
clearance of other drugs; amikacin clearance is reduced by
21 % and vancomycin clearance by 18 % when concomi-
tant ibuprofen is administered, and a higher decrease in
vancomycin clearance is observed during indomethacin
treatment [89].
In this scenario, we mention the use of caffeine citrate
(caffeine), largely prescribed as a first-line drug for the
treatment or prevention of apnea in preterm neonates [90].
It has been hypothesized that the hemodynamic effects of
caffeine might have long-term consequences on the health
status of previously exposed children. However, recent
studies show that even if caffeine administration in NICU
patients has short-term adverse effects, such as increased
heart rate, jitteriness, irritability, seizures [91], and delayed
weight gain [92], the survival rate of children up to 5 years
of age is improved for caffeine treatment compared with
placebo, without neurodevelopmental impairment [93].
Specific features of the neonatal kidney, which compli-
cate renal drug handling, may influence drug-induced toxi-
city. Neonates seem to be more sensitive to vasoactive
aspects (e.g. ibuprofen-induced reduction in GFR), and the
immaturity of allergic reaction capacity may facilitate the
onset of interstitial nephritis. The elimination of many drugs
is mediated by tubular kidney transporters, which have lower
activity in neonates [94]. This may cause intracellular ac-
cumulation of active substances; however, the implication of
these factors on drug elimination and the development of
nephrotoxicity in early infancy is a matter of investigation.
5 Strategies to Prevent Onset of Renal Damage
in the Neonatal Population
5.1 Biomarkers to Monitor Renal Safety of Drugs
Serum creatinine levels (sCr) are widely used in the diag-
nosis of AKI, but sCr-based definitions are not highly pre-
dictive because (1) sCr measures function, not injury; (2) sCr
may not change until 25–50 % of kidney function is com-
promised; (3) sCr overestimates renal function due to tubular
secretion of creatinine at lower GFRs; (4) sCr varies by
muscle mass, hydration status, sex, and age, and its mea-
surement can be affected by endogenous substances; (5) sCr
is not specific to different types of AKI; (6) in some condi-
tions, such as pre-renal azotemia, sCr might be non-specific
for AKI; and (7) sCr cannot be applied in the early postnatal
period because serum Cr reflects maternal kidney function.
In addition, sCr levels show significant variation, depending
also on the degree of prematurity [95, 96].
Table 3 Drugs most used in NICUs and nephrotoxicity [68, 70, 77, 83, 87]
Drug class/drug Mechanism of renal injury Clinical manifestations Risk factors
Aminoglycosides Acute tubular necrosis Increased serum creatinine, blood
urea nitrogen, reduction of urine
output
Decreased renal blood flow, volume depletion,
pre-existing renal insufficiency, duration and
repeated therapy, large cumulative doses,
concomitant use of potentially nephrotoxic
agents
Amphotericin B Acute tubular necrosis Increased serum urea and creatinine
concentration, hypokalemia,
metabolic acidosis,
hypomagnesemia
Pre-existing renal insufficiency, volume
depletion, large individual cumulative doses,
concomitant use of potentially nephrotoxic
agents
b-Lactams Acute interstitial nephritis Pyuria, eosinophiluria, low-grade
proteinuria, fever, skin rash
Long-term administration
Loop diuretics Nephrocalcinosis Hyponatremia, hypocalcemia,
hypochloremic alkalosis,
hypercalciuria
Rapid intravenous infusion, long-term
administration, concomitant use of potentially
nephrotoxic agents
Nonsteroidal
anti-
inflammatory
drugs
Acute interstitial nephritis,
altered intraglomerular
hemodynamics,
glomerulonephritis
Proteinuria, hypoalbuminemia,
hyperlipidemia, edema
Pre-existing renal insufficiency, volume
depletion, concomitant use of potentially
nephrotoxic agents
NICUs neonatal intensive care units
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The identification of novel biomarkers will allow early
detection of AKI and could improve patient outcomes [51].
Figure 3 provides a general overview on promising biomark-
ers for renal damage in the entire population (especially in
adults). In the neonatal population, the only biomarkers under
investigation are serum and urinary neutrophil gelatinase-as-
sociated lipocalin (NGAL), urinary interleukin (IL-18), os-
teopontin (OPN), kidney injury molecule-1 (KIM-1), b-trace
protein (BTP), and serum cystatin C (CysC).
Studies on AKI biomarkers in neonates have been
mainly performed in specific populations at risk, such as
VLBW, asphyxiated newborns, and children undergoing
cardiac surgery with cardiopulmonary bypass (CPB).
Although several new candidate biomarkers have been
studied, some turned out to depend on both gestational age
and birth weight. Moreover, the results of these studies are
often difficult to evaluate because sCr has been inappro-
priately used as the gold standard marker for AKI [97].
5.1.1 Neutrophil Gelatinase-Associated Lipocalin (NGAL)
This protein belongs to the family of lipocalin (NGAL) and
has been proposed as an early biomarker of AKI and CKD.
In these conditions, NGAL levels, which depend on distal
tubule production, are high in both blood and urine. Serum
and urinary levels are elevated in humans with AKI, in-
cluding neonates undergoing CPB surgery [98, 99] and
other critically ill pediatric populations [52, 100–102].
NGAL may also function as an iron-binding transporter
modulating essential life processes. In addition, NGAL
may play a role in cellular defense against toxic stimuli on
kidney and other epithelia, and in nephrogenesis, as a
mesenchymal differentiating factor produced by the
ureteric bud [103].
However, at the moment, inflammatory status and pre-
maturity limits the specificity of total NGAL measurement
as a marker of AKI [104].
5.1.2 Interleukin-18
IL-18 is one of the most studied biomarkers of AKI, and a
member of the IL-1 family of cytokines, synthesized as an
inactive 23 kDa precursor in several cells, including
monocytes, macrophages, and proximal tubular epithelial
cells. It is processed into an active 18.3 kDa cytokine by
caspase-1, and has been demonstrated in some animal
Fig. 3 Promising biomarkers for early detection of renal damage [98,
102, 105, 108, 116]. MIF macrophage migration inhibitor factor,
NGAL neutrophil gelatinase-associated lipocalin, KIM-1 kidney
injury molecule-1, GST-a a-glutathione S-transferase, VEGF vascular
endothelial growth factor, Timp-1 tissue inhibitor of metallopro-
teinase-1, NHE-3 sodium/hydrogen exchanger-3, L-FABP L-type
fatty acid-binding protein, HGF hepatocyte growth factor, NAG N-
acetyl-b-D-glucosaminidase, RBP retinol binding protein, TFF-3
trefoil factor 3, Cyr61 cysteine-rich protein-61, H-FABP H-type fatty
acid-binding protein, IL interleukin. Asterisk Biomarkers under
investigation in the neonatal population
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studies as a mediator of renal ischemia–reperfusion injury,
inducing acute tubular necrosis, and neutrophil and
monocyte infiltration of the renal parenchyma. Urinary IL-
18 may have an important role in non-septic, critically ill
neonates as a non-invasive biomarker to independently
predict AKI development during early life after birth [105].
Urinary IL-18 seems to be independent from renal ma-
turity, whereas it can be influenced by sepsis, thus reducing
its ability to detect AKI [97].
5.1.3 Cystatin C
CysC, a cysteine protease inhibitor, is predominantly lo-
calized in the proximal tubule of the cortex. In addition, it
was observed in the lumen of the renal tubule in the cortex,
corticomedullary junction, and medulla during the pro-
gression of renal damage, although its immune-reactive
area ratio was very low. Apparently, CysC does not cross
the placenta [105] and thus reflects the renal function of
neonates in early postnatal life regardless of body com-
position and size [106]. Serum CysC was identified as an
earlier marker of AKI in preterm neonates with respiratory
distress syndrome [51] and was also predictive of AKI in
non-septic, critically ill newborns [107].
Although other studies have evaluated CysC in older
children, it is difficult to extend their results to the neonatal
population, considering that normal values of urinary CysC
decrease with tubular maturation [97].
Urinary CysC, as an independent biomarker with greater
accuracy than urinary IL-18, could predict the development
of AKI in non-septic, critically ill neonates [107].
5.1.4 Kidney Injury Molecule-1
KIM-1, a transmembrane tubular protein with unknown
function, is undetectable in normal kidneys but is markedly
induced in experimental renal injury. The KIM-1 ectodo-
main is cleaved, detectable in urine, and reflects renal
damage. Urinary KIM-1 levels are strongly related to
tubular KIM-1 expression in experimental and human renal
disease. Studies in humans also indicated that urinary KIM-
1 was sensitive and a specific marker of injury as well as
predictors of outcome [108]. Recently, two systematic re-
views have reported that KIM-1 was an efficient novel
urinary biomarker in the diagnosis of AKI within 24 h after
kidney injury [108, 109], especially in the diagnosis of
ischemic injury [110]. However, due to small population
settings, heterogeneous patient type, few clinical trials, and
heterogeneity in detection time, the application of KIM-1
in the early diagnosis of AKI still needs to be validated by
larger studies. Moreover, age is still insufficiently
evaluated as an influencing factor [111].
5.1.5 b-Trace Protein
BTP is a low-molecular-weight protein belonging to the
lipocalin protein family. In adult patients, serum BTP is
reported to inversely correlate with GFR, and increases
with renal diseases [112]. In the neonatal population, BTP
is shown to be independent from gestational age and
muscle mass, and is a good predictor of GFR reduction
[113, 114]. Ranges for serum BTP in term and preterm
neonates have been provided and a steady decline of BTP
values with increasing age was observed [115]. In the
newborn population, threshold values for AKI identifica-
tion have not yet been defined [114].
5.1.6 Osteopontin
The cytokine OPN is involved in the pathophysiology of
experimental acute kidney injury and could be a specific
biomarker of AKI in the case of loop of Henle damage.
In the neonatal population, a nested case-control study
[102] in 30 patients (only nine with AKI) showed that AKI
newborns had greater OPN values than controls. Prospec-
tive studies are needed to ascertain OPN value in predicting
neonatal AKI.
5.1.7 b2-Microglobulin
Tubular proteinuria is traditionally referred to low-mole-
cular-weight proteins that are normally produced in the
body, freely filtered across the glomerulus, and normally
reabsorbed in the proximal tubule but appear in the urine
due to proximal tubular damage. Examples include a1-
microglobulin, b2-microglobulin, and retinol-binding pro-
tein. b2-microglobulin is a 12-kD protein, is part of the
class I major histocompatibility complex, and is presented
at the membrane of nucleated cells. Urinary concentration
may rise after toxins (radiocontrast) or cardiac surgery, or
transplantation-induced renal injury, but may poorly pre-
dict the need for renal replacement therapy. Also, the
concentration of b2-microglobulin increases with
glomerular diseases, and an increase in b2-microglobulin
may be predictive for a decrease in renal function. There-
fore, b2-microglobulin may not be a specific marker of
tubular injury [116].
Recently, more and more experts have suggested that a
combination of multiple biomarkers to form a biomarkers
panel was an optimal way to detect AKI more efficiently
and accurately [107].
5.1.8 Metabolomics
Metabolomics represents an efficient way to contem-
porarily measure many biomarkers by analysing global sets
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of low-molecular-weight metabolites (including amino
acids, organic acids, sugars, fatty acids, lipids, steroids,
small peptides, vitamins, etc.), thus providing a ‘snapshot’
of the metabolic status of a cell, tissue, or organism in
relation to genetic variations or external stimuli. The use of
metabolomics appears to be a promising tool in neona-
tology. Urine is a biofluid particularly suitable for meta-
bolomic analysis in neonatology because it may be
collected by using simple, non-invasive techniques and
may provide valuable diagnostic information [117].
The field of metabolomics uses analytical techniques
such as nuclear magnetic resonance (NMR) spectroscopy
and mass spectrometry (MS) to identify and quantify a
sample’s metabolite pool. Quantification of metabolites
serves not only as a biomarker of certain cellular or tissue
injuries but also to elucidate mechanisms of AKI.
5.2 Pharmacokinetic Aspects
The real impact of immaturity on drug disposition in this
population has not been fully defined, especially because of
the great heterogeneity in disease characteristics and
comedications, in addition to age (postnatal, postmenstru-
al), and, moreover, because performing pharmacokinetic
studies in the neonatal population remains challenging. A
novel and promising approach to improve drug therapy and
to facilitate studies in neonates and young infants is
knowledge integration through pharmacokinetic modeling,
which is either driven by mechanism-based pharmacoki-
netics or by physiology-based pharmacokinetics. Mechan-
ism-based models use a ‘from compound to model’
approach; based on compound-specific observations, co-
variates are described, resulting in mechanism-based
models that reflect a semiphysiological maturational
function [118–120]. In contrast, physiology-based phar-
macokinetics use a ‘from physiology to clinical observa-
tions’ approach; driven by characteristics of neonatal
physiology (e.g. weight, cardiac output, renal function) and
anatomy, as well as its age-related changes, a physiology-
based pharmacokinetic model is developed [118–120].
Population pharmacokinetic approaches hereby provide a
statistical tool to study and explore variability in pediatric
drug responses among and within individuals representa-
tive of those in whom the drug will be used clinically [121–
123]. Such models can drive study design and convert
neonatal pharmacological studies from explorative to
confirmatory [121–123]. Once a model is developed,
validation is needed in a prospective trial. This method-
ology will improve dosing guidelines at the individual level
[121–123].
The feasibility of these concepts for GFR-driven clear-
ance in neonates has been described using a stepwise ap-
proach. In the first step, amikacin clearance was predicted
by weight at birth (maturation until delivery), postnatal age
(maturation since delivery), and disease characteristics
(ibuprofen exposure, peripartum asphyxia) [124]. Since
amikacin clearance reflects GFR ontogeny, it is reasonable
to assume that the same pharmacokinetic model and its
covariates will also accurately predict clearance maturation
of other compounds that are cleared by the same route.
Using datasets of netilmicin, vancomycin, tobramycin, and
gentamicin in neonates, it was confirmed that the perfor-
mance of the amikacin GFR model was similar to the in-
dependent, compound-specific models [125]. This provides
evidence that the neonatal amikacin covariate model in-
deed contains physiological information since the infor-
mation extracted from the first dataset on a given
compound can be extrapolated to another compound that
undergoes elimination by the same route as long as the
clinical characteristics remain similar. Consequently, the
same approach has been used to describe GFR maturation
throughout life [125].
A very specific covariate that also needs further explo-
ration in combination with all the aforementioned aspects
on drug-related renal toxicity in preterm neonates is the
relation between pharmacogenomics, drug disposition, and
drug-induced renal damage. The preterm newborn is defi-
cient in drug-handling capacity, including drug me-
tabolizing enzymes (e.g. cytochromes P450), drug
transporters (e.g. renal tubular organic anion transporters),
or receptors (e.g. renin-angiotensin-aldosterone system,
dopamine) [4]. This immature drug-handling capacity may
potentially be superimposed to genetic polymorphisms
determining drug metabolism and transport, thereby further
increasing the interpatient variability in drug dose, re-
sponse, and renal side effects [126]. To illustrate the po-
tential relevance of pharmacogenetic, polymorphism-
driven renal drug toxicity, we refer to the work on ifos-
famide in infants and toddlers [127].
6 Ongoing Research Initiatives and Consortia
The lack of clinical evidence supporting pharmacological
treatments in newborns calls for investigations focused on
this population. Table 4 reports some of these, aimed at
validating dosage regimen and evaluating the short-term
safety of single agents belonging to the anti-infective class.
Among recently launched funding programs of the
European Commission, a call topic is specifically devoted
to the improvement of healthcare interventions in the pe-
diatric population, aimed at decreasing the risk of treat-
ments and filling the gap of knowledge on healthcare
interventions.
Research on preterm neonates may be very challenging
because of well-known technical issues (multi-organ
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immaturity, prematurity, lack of self-assessment, need for
specific formulations, etc.), the great heterogeneity in
clinical practice, and the restricted number of neonates
prematurely born with a given disease in each center. Thus,
it is important to support and improve already existent
networks in order to study the actual clinical practice
among countries, and integrate the risk-benefit profiles of
the currently used and new medicines among NICUs for
the creation of international guidelines for the management
of preterm babies.
7 Conclusions and Perspectives
The specific pharmacokinetic and pharmacodynamic
aspects of neonates need to be further investigated in
order to improve drug use. In this sense, the develop-
ment of physiology-based pharmacokinetic models is a
promising approach that could facilitate studies in
neonates and improve drug therapy [121]. In addition
to the pharmacokinetic and pharmacodynamic pecu-
liarities, the preterm population is characterized by
organ immaturity and specific pathological conditions
(e.g. respiratory distress syndrome, PDA) [3], improv-
ing risk of drug-related injuries. In particular, AKI is
very common among NICUs [49] and correlates with
higher mortality rates [50] and increased long-term risk
of CKD [63–65].
Many of the widely used therapeutics in NICUs could
impair renal function, either because of their well-known
nephrotoxicity (i.e. aminoglycosides [77], b-lactam an-
tibiotics [70], amphotericin B [83]) and their interaction
with renal developmental factors (e.g. furosemide [87],
NSAIDs [77]), but also because specific conditions af-
fecting preterm neonates are correlated to AKI [51–54].
Difficulties still exist in discriminating the role of multiple
factors (drugs, diet, age-related organ immaturity, diseases)
in determining the onset of kidney damage. In this context,
the validation of biomarkers for the early detection of renal
injury could significantly improve clinical practice in this
population.
Neonates, especially those born prematurely, can be
considered an ‘orphan’ population with regard to
specifically approved drugs [16–27]. Because of inherent
difficulties in carrying out clinical trials in preterm infants,
the collection of ‘real-world’ data is necessary to fully
address clinical issues. The creation of multinational,
multidisciplinary consortia is an approach with great po-
tential to identify and compare real-world practice and
relevant outcomes in NICUs. More specifically, the fol-
lowing areas need further investigation:
1. The development of pharmacokinetic-pharmacody-
namic models is a promising approach to address
specific pharmacokinetic and pharmacodynamic
aspects, and can improve drug therapy also through
dose optimization [121].
2. Since the preterm population is characterized by organ
immaturity and specific disorders [3], reducing the risk
of drug-related injuries must be addressed by active
pharmacovigilance. Although some difficulties remain
in discriminating the role of multiple factors in
determining kidney damage (drugs, diet, age-related
organ immaturity, diseases), some of these, such as
drugs and diet, are certainly modifiable. The creation
of networks for conducting postmarketing surveillance
of emerging safety issues based on ‘real-world’ data in
preterm neonates fits well with the new European
pharmacovigilance legislation, which aims at strength-
ening the post-authorization monitoring of medicinal
products and now includes adverse reactions observed
with off-label use.
3. Identification of drug- and patient-related characteris-
tics associated with a higher risk of renal damage and
related clinical sequelae will allow the development of
risk scores and risk charts, which are actually missing
in neonatology. The incorporation of validated renal
function biomarkers into clinical practice will truly
allow personalized medicine [128, 129].
The increased interest of regulatory agencies and fund-
ing programs in the neonatal population reflects the need
for international guidelines for the management of new-
borns, and also calls for international consortia, which
should plan observational studies to systematically access
the current clinical practice in NICUs. After careful review
of current real-world practices across countries, a more
Table 4 Clinical trials, funded by European Commission, in the neonatal population
Name Drugs under investigation Partners Duration of the study
TINN (www.tinn-project.org) Ciprofloxacin and fluconazole 16 partners from seven EU states 2008–2012
TINN2 (www.tinn2-project.org) Azythromycin 16 partners from nine EU states 2011 (ongoing)
NeoMero (www.neomero.org) Meropenem PENTA and TEDDY networks 2009 (ongoing)
NeoVanc (www.neovanc.org) Vancomycin Consortia of TINN, TINN2 and NeoMero projects 2013 (ongoing)
PENTA Paediatric European Network for the Treatment of AIDS, TEDDY Task force in Europe for Drug Development in the Young
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informed strategy will be achievable towards improvement
of clinical recommendations and more informed regulatory
decisions.
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